Clinical trial · Observational
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study
NCT06321679CI-TRIAL-00075260RESPECTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imaging evaluation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- WB-MRI
- description
- Each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
- interventionNames
- Procedure: Imaging evaluation
Primary outcomes (1)
- measure
- Time to disease progression in bone metastasis identify by WB-MRI
- timeFrame
- 192 weeks
- description
- the proportion of WB-MRI examinations that identify disease progression in bone metastases prior to CT + BS
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of castration-resistant prostate cancer, * Single or multiple bone metastases, * Life expectancy of over 6 months, * No current active malignancy other than prostate cancer, * Provision of written informed consent. Exclusion Criteria: * Absolute contraindication to WB-MRI, CT or BS, * Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion), * Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.
References
Publications (0)
Data not yet available
No reference posted for this study.